BiotechTube

DS-5670a + Placebo

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Covid19

Conditions

Covid19

Trial Timeline

Mar 15, 2021 → Jul 14, 2022

NCT ID
NCT04821674

About DS-5670a + Placebo

DS-5670a + Placebo is a phase 1/2 stage product being developed by Daiichi Sankyo for Covid19. The current trial status is completed. This product is registered under clinical trial identifier NCT04821674. Target conditions include Covid19.

What happened to similar drugs?

4 of 16 similar drugs in Covid19 were approved

Approved (4) Terminated (5) Active (9)
✅Icosapent ethylAmarin CorporationApproved
✅bamlanivimabEli LillyApproved
✅COVID-19 vaccine Pfizer (3 doses) + COVID-19 vaccine Pfizer (2 doses) + COVID-19 mRNA Vaccine Moderna (3 doses) + COVID-19 mRNA Vaccine Moderna (2 doses) + COVID-19 mRNA Vaccine Moderna (1 dose)SanofiApproved
✅Moderna mRNA-1273 COVID-19 vaccine + Pfizer BNT162b2 COVID-19 vaccineAllergy TherapeuticsApproved
❌AVIGAN + Placebo ComparatorDr. Reddy's LaboratoriesPhase 3
❌BaricitinibEli LillyPhase 3
🔄LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814Eli LillyPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04821674Phase 1/2Completed

Competing Products

20 competing products in Covid19

See all competitors
ProductCompanyStageHype Score
AVIGAN + Placebo ComparatorDr. Reddy's LaboratoriesPhase 3
29
Favipiravir + NitazoxanideStrides PharmaPhase 2
35
Icosapent ethylAmarin CorporationApproved
25
GX-03 + Petrolatum ointmentTurn TherapeuticsPhase 2
25
Cytotoxic T LymphocytesTevogen BioPhase 1
19
Pegylated Interferon-α2bZydus LifesciencesPhase 2
27
BaricitinibEli LillyPhase 3
32
LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814Eli LillyPhase 3
40
bamlanivimabEli LillyApproved
35
1x10^9 vp AZD1222 + 5x10^9 vp AZD1222 + 1x10^10 vp AZD1222AstraZenecaPhase 1
25
Sacubitril / Valsartan Oral Tablet [Entresto] + PlaceboNovartisPhase 1/2
32
PirfenidoneRochePre-clinical
26
Remdesivir + Remdesivir Placebo + CorticosteroidGilead SciencesPhase 3
40
RemdesivirGilead SciencesPre-clinical
26
Remdesivir + Remdesivir Placebo + Aviptadil + Aviptadil Placebo + CorticosteroidGilead SciencesPhase 3
40
anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)PfizerPhase 3
36
Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine + CoronaVac COVID-19 vaccine + ChAdOx1 nCoV-19 Covid-19 Vaccine + Ad26.COV2.S COVID-19 VaccinePfizerPre-clinical
26
Tofacitinib 10 mg + PlaceboPfizerPhase 3
40
BNT162b2PfizerPhase 2
35
Anakinra + 0.9% SalineSwedish Orphan BiovitrumPhase 2
27